| 3.65 0.28 (8.31%) | 08-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.83 | 1-year : | 5.95 |
| Resists | First : | 4.13 | Second : | 5.09 |
| Pivot price | 3.2  |
|||
| Supports | First : | 2.57 | Second : | 2.14 |
| MAs | MA(5) : | 3.33  |
MA(20) : | 3.24 |
| MA(100) : | 6.06 |
MA(250) : | 17.42 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 46.2 |
D(3) : | 35.1 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 55.9 | Low : | 2.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SHPH ] has closed below upper band by 15.6%. Bollinger Bands are 57.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.65 - 3.67 | 3.67 - 3.69 |
| Low: | 3.29 - 3.31 | 3.31 - 3.33 |
| Close: | 3.62 - 3.65 | 3.65 - 3.68 |
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Mon, 03 Aug 2026
Shuttle Pharmaceuticals (SHPH) seeks approval for major Dogecoin-driven share issuance - Stock Titan
Sun, 02 Aug 2026
SHPH Surges After HRT Financial Boosts Stake - timothysykes.com
Sat, 01 Aug 2026
SHPH Surges As HRT Financial Buying Triggers 65% Spike - timothysykes.com
Fri, 31 Jul 2026
SHPH|Shuttle Pharmaceuticals Holdings Inc|Price:3.364|Chg%:-0.436 - TradingKey
Sun, 26 Jul 2026
Shuttle Pharmaceuticals Holdings, Inc. Revenue Breakdown – NASDAQ:SHPH - TradingView
Wed, 15 Jul 2026
Insider Sell: Financial Hrt Sells 83,149 Shares of Shuttle Pharm - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 430 (K) |
| Shares Short P.Month | 33 (K) |
| EPS | 0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -81.7 % |
| Return on Equity (ttm) | -326.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -18.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 36.5 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|